Related Experiment Video
Updated: Dec 24, 2025
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
miR-150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B-cell lymphoma
Xinyuan Wang1, Yutian Kan1, Leiyuan Chen1
1Department of Hematology and Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, P.R. China.
Abstract:
A number of studies suggest an association between miRNAs and diffuse large B-cell lymphoma (DLBCL). The present study aimed to investigate the prognostic value of microRNA (miR-150) in primary gastrointestinal (PGI)-DLBCL, by assessing the association between miR-150 expression and clinicopathological characteristics in patients with PGI-DLBCL. A total of 84 patients diagnosed with PGI-DLBCL were recruited and both tumor and adjacent non-tumor tissue samples were collected. miR-150 expression was assessed via reverse transcription-quantitative (RT-q)PCR analysis. The results demonstrated that miR-150 expression was significantly lower in PGI-DLBCL tissues compared with adjacent non-tumor tissues. Furthermore, receiver operating characteristic (ROC) curve analysis indicated that the optimal cut-off value of miR-150 for predicting survival was 8.965 with high sensitivity (79.8%) and specificity (77.1%). Patients were divided into two groups according to this cut-off value, as follows: High (n=18) and low expression (n=66) groups. Low miR-150 expression was significantly associated with clinical stage, International Prognostic Index (IPI), Eastern Cooperative Oncology Group status and use of rituximab. RT-qPCR analysis demonstrated that miR-150 expression was significantly lower in patients with high IPI scores compared with patients with low IPI scores. Downregulated miR-150 expression was significantly associated with shorter overall survival (OS) time and progression-free survival (PFS) time in patients with PGI-DLBCL. Furthermore, miR-150 level and IPI score were identified as two risk factors for OS and PFS. The diagnostic value of miR-150 was evaluated via ROC curve analysis, with an area under the curve value of 0.882. Taken together, the results of the present study suggest that miR-150 is a potential diagnostic marker of PGI-DLBCL, and may also serve as a useful prognostic factor for survival outcomes in patients with PGI-DLBCL.
Insights
This study reveals that microRNA (miR-150) is significantly lower in primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) tissues. Low miR-150 expression serves as a potential diagnostic marker and prognostic factor for PGI-DLBCL patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous hematologic malignancy.
- MicroRNAs (miRNAs) play crucial roles in lymphomagenesis and have emerged as potential biomarkers.
- Primary gastrointestinal DLBCL (PGI-DLBCL) presents unique clinical challenges and prognostic factors.
Purpose of the Study:
- To investigate the prognostic value of microRNA (miR-150) in patients with PGI-DLBCL.
- To assess the association between miR-150 expression levels and clinicopathological characteristics.
- To evaluate miR-150 as a potential diagnostic and prognostic biomarker for PGI-DLBCL.
Main Methods:
- Retrospective analysis of 84 PGI-DLBCL patients.
- Quantification of miR-150 expression in tumor and adjacent non-tumor tissues using reverse transcription-quantitative PCR (RT-qPCR).
- Correlation analysis between miR-150 levels, clinicopathological features, and survival outcomes (Overall Survival - OS, Progression-Free Survival - PFS).
- Receiver Operating Characteristic (ROC) curve analysis for diagnostic and prognostic value assessment.
Main Results:
- miR-150 expression was significantly lower in PGI-DLBCL tissues compared to non-tumor tissues.
- Low miR-150 expression correlated with advanced clinical stage, higher International Prognostic Index (IPI) scores, poorer Eastern Cooperative Oncology Group (ECOG) status, and rituximab use.
- Downregulated miR-150 was significantly associated with shorter OS and PFS.
- ROC analysis indicated miR-150 as a potential diagnostic marker (Area Under Curve = 0.882) and prognostic factor.
Conclusions:
- miR-150 is significantly downregulated in PGI-DLBCL.
- Low miR-150 expression is a potential diagnostic biomarker for PGI-DLBCL.
- miR-150 serves as a valuable prognostic factor for survival outcomes in PGI-DLBCL patients, independent of IPI score.
More Related Videos
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023